• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Nektar Therapeutics

    10/31/25 11:05:02 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 14)


    Nektar Therapeutics

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    640268306

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    640268306


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    106,881.00
    7Sole Dispositive Power

    833,793.00
    8Shared Dispositive Power

    114,854.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    948,647.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.98 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Nektar Therapeutics
    (b)Address of issuer's principal executive offices:

    455 Mission Bay Blvd South, San Francisco, CA, 94158
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    640268306
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    948647
    (b)Percent of class:

    4.98  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    106881

     (iii) Sole power to dispose or to direct the disposition of:

    833793

     (iv) Shared power to dispose or to direct the disposition of:

    114854

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:10/31/2025
    Get the next $NKTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NKTR

    DatePrice TargetRatingAnalyst
    6/24/2025$60.00 → $100.00Buy
    BTIG Research
    6/24/2025$6.50 → $120.00Buy
    H.C. Wainwright
    4/11/2025$2.00Hold → Buy
    Jefferies
    3/14/2025$6.00Perform → Outperform
    Oppenheimer
    1/8/2025$4.00Buy
    B. Riley Securities
    12/10/2024$6.50Buy
    H.C. Wainwright
    11/4/2024$7.00Overweight
    Piper Sandler
    9/30/2024$4.00Buy
    BTIG Research
    More analyst ratings

    $NKTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

    Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dosing with rezpegaldesleukin q2w supports 24-week induction period for planned Phase 3 studies with improvement across major efficacy endpoints from Week 16 to 24, including EASI-75, EASI-90, and vIGA-AD Data from long-term maintenance portion of REZOLVE-AD with 52 weeks of treatment expected in Q1 2026 from REZOLVE-AD study Top-line Phase 2b data for rezpegaldesleukin in alopecia areata to be reported in December 2025 SAN FRANCISCO, Nov. 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) t

    11/8/25 5:45:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics Reports Third Quarter 2025 Financial Results

    SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the third quarter ended September 30, 2025. Cash and investments in marketable securities on September 30, 2025 were $270.2 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities at September 30, 2025 includes $107.2 million of net proceeds from the secondary offering closed on July 2, 2025 and $34.3 million of net proceeds for the issuance of registered stock under the Company's filed at-the-market, "ATM", offering. Fo

    11/6/25 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

    SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London. Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 – webcast to be available at 11:00 a.m. Greenwich Mean Time / 3:00 a.m. Pacific Time – link hereThe fireside chat will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-

    10/30/25 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Whitfield Roy A

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    10/1/25 7:52:37 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Greer R Scott

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    10/1/25 7:51:55 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chess Robert

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    10/1/25 7:51:27 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    SEC Filings

    View All

    Nektar Therapeutics filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

    11/10/25 6:31:01 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Nektar Therapeutics

    10-Q - NEKTAR THERAPEUTICS (0000906709) (Filer)

    11/6/25 5:58:42 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

    11/6/25 4:24:36 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on Nektar Therapeutics with a new price target

    BTIG Research reiterated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $100.00 from $60.00 previously

    6/24/25 2:02:55 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Nektar Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $120.00 from $6.50 previously

    6/24/25 1:36:32 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics upgraded by Jefferies with a new price target

    Jefferies upgraded Nektar Therapeutics from Hold to Buy and set a new price target of $2.00

    4/11/25 8:15:16 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Leadership Updates

    Live Leadership Updates

    View All

    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    1/22/24 8:23:00 AM ET
    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors

    BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and

    5/11/22 8:01:00 AM ET
    $NKTR
    $TWST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.

    SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple

    11/15/21 8:30:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Financials

    Live finance-specific insights

    View All

    Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. 

    10/28/25 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. T

    7/31/25 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

    Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms versus placebo Achieved statistical significance for key secondary endpoints at week 16 of disease reduction, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA Rapid onset of EASI reduction and magnitude of itch improvement show potential differentiation of this novel regulatory T-cell mechanism as a first and best-in-class immune-modulator Robust dose-dependent reduction of inflammatory biomarkers in atopic dermatitis including TARC/CCL17, periostin, MDC/CCL22, and IL-19 Safety profile consistent with previously reported results Data expec

    6/24/25 7:30:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 12:17:04 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nektar Therapeutics

    SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 9:18:10 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    3/15/24 4:18:49 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care